| Name: | Amikacin EP Impurity C |
| Catalogue No. | VL6230003 |
| CAS No. | 50725-25-2 |
| Molecular Formula | C22H43N5O13 |
| Molecular Weight | 585.60 g/mol |
| Status | In-Stock |
| IUPAC Name | (S)-4-Amino-N-((2S,3R,4S,5S,6R)-2-(((1S,2R,3R,4S,6R)-4,6-diamino-3-(((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-hydroxybutanamide;4-O-(6-Amino-6-deoxy-α-D-glucopyranosyl)-6-O-[3-[[(2S)-4-amino-2-hydroxybutanoyl]amino]-3-deoxy-α-D-glucopyranosyl]-2-deoxy-D-streptamine |
| Description | Amikacin EP Impurity C (CAS No: 50725-25-2) is an impurity witnessed in the production of amikacin that is a semisynthetic aminoglycoside which is refractory to the largest aminoglycoside modifying enzymes used for the treatment of severe infections caused by Gram-negative bacteria. |
| References | Ramirez, Maria, and Marcelo Tolmasky. “Amikacin: Uses, Resistance, and Prospects for Inhibition.” Molecules, vol. 22, no. 12, Dec. 2017, p. 2267,https://doi.org/10.3390/molecules22122267.Wang, Jian, et al. “Separation and Characterization of Unknown Impurities in Amikacin Sulfate by HPLC–MS N.” Chromatographia, vol. 78, no. 15-16, May 2015, pp. 1031–39,https://doi.org/10.1007/s10337-015-2909-8. |
